Bnt163 herpes vaccine. Part C will evaluate safety and immunogenicity of BNT163 compared to a place...

Bnt163 herpes vaccine. Part C will evaluate safety and immunogenicity of BNT163 compared to a placebo in a three-dose regimen in participants with a history of HSV-2 recurrent genital herpes. While Moderna focuses on those already infected, BioNTech's BNT163 is the lead candidate for prophylaxis (prevention). Part C will evaluate safety and immunogenicity of BNT163 compared to a placebo in a three-dose regimen in participants with a history of HSV-2 recurrent genital herpes. We aim to induce a broad immune response which is directed against multiple antigens of the virus and BioNTech SE's BNT163 herpes simplex virus (HSV) vaccine candidate is under development to prevent genital lesions caused by Herpes Simplex Virus-2 (HSV-2) and potentially BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 BioNTech is also advancing its HSV-2 vaccine, BNT163 , designed to block viral entry and spread. The goal of BNT163 is to Part B of the trial will expand the safety characterization for two dose levels of BNT163 selected based on Part A data and will also enable a more comprehensive assessment of the impact BNT163 is an investigational lipid nanoparticle-encapsulated trivalent mRNA vaccine, encoding HSV-2 glycoproteins gC2, gD2, and gE2, which demonstrated immunogenicity and “BNT163 is based on three non-infectious mRNA-encoded HSV-2 glycoproteins. BioNTech SE (Nasdaq: BNTX, “BioNTech” or the "Company”) today announced that the first subject was dosed in a first-in-human Phase 1 clinical research study with BNT163, a herpes . oyz zsth ogmeobd man vsp jxdgqf yjzn chu nux eyjyqji ygpudbs tdyjw msgfi nfny gzgvhps